Missouri Senate debates SB54 to reclassify hemp-derived intoxicants; amendment to grandfather existing vendors fails

The Missouri Senate spent much of its April 8 session debating Senate Bill 54, a bill that would bring intoxicating cannabinoids derived from hemp under the regulatory framework used for marijuana.

Sponsor arguments focused on public-health data and gaps in federal oversight. "It is a public health crisis," the Senator from the second said, arguing that chemically converted hemp products are sold to minors in convenience stores and lack testing for potency and contaminants. The sponsor cited poison-control and hospitalization trends in arguing for age limits, testing, labeling and licensing similar to the existing marijuana regulatory system.

Opponents countered that the substitute before the chamber would impose an unfair, industry-wide reclassification that largely benefits existing dispensary license holders and risks shutting long-established, USDA-registered hemp manufacturers out of retail channels. "It's creating an unfair business advantage to 1 group over another," the Senator from the fourth said repeatedly, urging a path that regulates — rather than folds — legitimate hemp businesses into the marijuana market.

Lawmakers pressed the sponsor and each other on technical points that repeatedly surfaced: which products the federal Farm Bill actually preempts, whether the U.S. Department of Agriculture or ISO/IEC‑17025 accredited labs should certify tests, how to police online or out‑of‑state imports, and whether Missouri can or should alter a voter-approved constitutional framework that already governs marijuana (Amendment 3). Senators discussed multiple compliance proposals offered on the floor: an age-21 sales restriction, behind‑the‑counter retail placement, QR-coded certificates of analysis, retail and manufacturing licenses, spot checks paid by manufacturers, an excise tax, and a proposed 45‑day window to bring existing sellers into a new license regime.

Several amendments were offered. The senator from the fourth proposed an amendment that would have required licensing, ISO/IEC testing and other guardrails while grandfathering existing in‑state manufacturers; she also proposed a 45‑day period for existing vendors to come into compliance. That amendment was debated at length and put to a standing-division vote; by division the amendment failed, 8 yes to 16 no. A subsequent amendment to require age‑21 verification in statute was also defeated during the amendment process.

Supporters of SB54 said the bill closes a federal loophole that has led to a rapid growth in retail availability of intoxicating hemp derivatives (delta‑8, delta‑10 and other variants), and they cited national and state-level reports of pediatric exposures and emergency-room visits. Opponents said tighter, targeted retail rules would secure products from minors without collapsing the two industries into one and that carving existing hemp producers out of retail distribution would cut small businesses and reduce affordable access for some patients and caregivers who use hemp-derived products.

No final vote on adoption of the senate committee substitute was recorded in the transcript of this session. Debate continued past multiple amendment attempts, and floor leaders paused when a quorum call was requested after extended discussion.

Votes at a glance - Motion to take up Senate Bill 54 for perfection: moved by the Senator from the second and approved on the floor (procedural voice agreement). - Senate amendment by the Senator from the fourth (grandfathering + licensing package): failed by standing division, 8 yes, 16 no. - Subsequent amendment requiring age‑21 verification (amendment to amendment): failed on a voice vote. - No final passage of the substitute or of SB54 was recorded in the transcript; consideration remained active at adjournment.

Why this matters The bill would change which state agencies set testing, labeling and sales rules and where those products may be sold. Proponents say uniform rules will reduce untested products on store shelves and keep intoxicants away from children; opponents say the measure would displace legitimate, USDA‑registered hemp manufacturers and concentrate distribution in dispensaries created under Amendment 3. The debate touches federal preemption, constitutional constraints, commerce flows across state lines, industry transition costs and public‑health tradeoffs.

What was decided and what’s next The senate did not complete final passage of SB54 during the session excerpted in this transcript. Several amendment attempts failed on the floor. The bill remained under active consideration at adjournment, with senators continuing to negotiate carve‑outs, licensing timelines and technical changes around testing standards and enforcement.

Sources and context Senators cited the 2018 Farm Bill, federal USDA hemp testing guidance, warnings from the FDA and published studies (including JAMA) as background for the public‑health claims, and repeatedly referenced Missouri’s voter‑approved Amendment 3 and existing statute related to controlled‑substance analogs (RSMo sections discussed on the floor). Specific policy proposals discussed on the floor included: age‑21 verification, ISO/IEC‑17025 lab testing, behind‑the‑counter sales, a retail license regime, a 45‑day grandfathering window and up to 10 spot tests per manufacturer per year paid by the manufacturer.